Midgard Science
I

Iasobio

Nanjing, China iasobio.com From their website, Nov 2026

  • GMP

Work here? Claim this listing

About

IASO Bio develops cell therapies and biologics for hematologic malignancies and autoimmune diseases. It operates in Nanjing, Shanghai, and Pleasanton, with global R&D, clinical, and manufacturing activities spanning discovery through commercialization.

Iasobio is a CRDMO in Nanjing, China, founded in 2017. It lists 9 services, including Fully Human Antibody Discovery Platform, High-throughput CAR-T Cell Therapy Screening and Optimization Platform and In Vivo CAR-T Platform. It names GMP on its listing.

Services

  • Fully Human Antibody Discovery Platform

    Uses a fully human antibody library of over 240 billion antibodies, plus synthetic and single-domain libraries, to support discovery of antibody candidates and next-generation therapies.

  • High-throughput CAR-T Cell Therapy Screening and Optimization Platform

    Uses single-cell analysis and next-generation sequencing to screen and optimize CAR-T lead candidates based on phenotypic and functional metrics.

  • In Vivo CAR-T Platform

    Develops in vivo CAR-T products using viral vector engineering, T cell-specific promoters, and proprietary envelope modifications to improve selective T cell transduction and safety.

  • Advanced Manufacturing and CMC Platform

    Provides end-to-end manufacturing and quality systems to support development and commercial-scale production of cell and gene therapy products.

  • Plasmid Manufacturing

    Produces research, GMP-grade, and injectable-grade plasmids using fermentation, purification, in-process analytics, sterilization, and Class A filling.

  • Lentiviral Vector Manufacturing

    Produces lentiviral vectors in a closed, automated, scalable system with batch release testing for identity, potency, sterility, residual DNA, and host-cell protein.

  • Cell Process Development and Manufacturing

    Develops cell products for GMP-compliant manufacturing and supports GMP grade plasmids, viral vectors, and cells.

  • Clinical Development and Clinical Translational Research Platform

    Operates a joint laboratory with a top-tier Chinese hospital to integrate research and clinical development.

1 more services
  • Cell product process development and GMP manufacturing
What to send
  • Single intravenous infusion of IASO208
  • Patients are not required to undergo conventional apheresis or lymphodepleting conditioning

How to order from Iasobio

What to send, as they list it: Single intravenous infusion of IASO208; Patients are not required to undergo conventional apheresis or lymphodepleting conditioning. They take requests through the contact form on their website. You can contact them directly from this page, or request a quote through Midgard.

Capabilities

Assays and studies
  • Cell therapy
  • In vivo
  • Antibodies
  • Lentivirus
  • NGS
  • Flow cytometry
12 more
  • Process development
  • Single-cell analysis
  • Next-generation sequencing
  • Molecular detection
  • Cell function assays
  • Identity testing
  • Potency testing
  • Sterility testing
  • Residual DNA testing
  • Host-cell protein assays
  • Cell function testing
  • Host-cell protein testing
Scale and capacity
  • Nanjing Facility: approximately 7,866 square meters GFA
  • Shanghai Facility: 32,306 square meters GFA
  • Four global R&D and manufacturing sites
  • Fully integrated platforms spanning the entire product lifecycle
  • Over 240 billion antibodies in the fully human antibody library
  • Ten products and product candidates
Therapeutic areas
  • Hematological malignancies
  • Autoimmune diseases
  • Multiple myeloma
  • Relapsed/refractory B-cell non-Hodgkin lymphoma
  • B-cell malignancies
  • Myasthenia gravis
4 more
  • Multiple sclerosis
  • Systemic lupus erythematosus
  • Lupus nephritis
  • B-cell non-Hodgkin lymphoma

Modalities and species

Modalities
  • Antibody
  • Bispecific
  • mRNA
  • Viral vector
  • Cell therapy
  • Gene editing
  • Plasmid DNA

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

    Scope: cell product process development

Industries served

  • Advanced therapy medicinal products
  • Cell therapy
  • Gene therapy

Company

Type
CRDMO
Founded
2017

Locations

Address
1 Xinjinhu Road, Jiangbei New District, Nanjing, Jiangsu Province 210018
Sites
  • Shanghai, China
  • Pleasanton, United States
  • Pleasanton, CA, United States
Serves
China, United States, Singapore, Saudi Arabia, United Arab Emirates, Hong Kong, Japan, Australia, Korea

Contacts

Similar labs